Innovation. Experience. Results.
Home | 
About Us | 
Contact Us | 
Glossary | 

MZB Foundation

About The MZB Foundation

MZB Cancer Research Foundation, Oncology Laboratory



MZB work has discovered a way to make unsafe and mediocre chemotherapy and smart target drugs both safer and more effective. The work has safely combined smart and cytotoxic drugs others have found very difficult to combine. The resulting responses include new safe therapeutic opportunities and possible cures for some patients with a wide variety of cancers, including multiline, line refractory, Ovarian, Uterine, Pancreatic, Cholangio, Gastric Esophaeal, ColoRectal, HEENT, and Lung cancers.


Intermediate safe doses replace high toxic doses. Cores of four drugs replace single drugs as partners for these difficult target drugs. Fifth and sixth drugs can often be safely added as needed serially to the four drug cores.


So called Standard and Assay Best Drugs are rejected in favor of "weaker" less potent inhibitor drugs, because the weaker drug proxies better synergism net effect and has a favorable safer side effect pattern.


These drugs are preferred because they have special advantages that can be detected in the lab and exploited (translated to) in the clinic. These weaker core drugs are better safer team players and are suitable for empirical therapy. They can be used initially without special tumor tests.


Drug position, order of use, can be changed, based on game theory, like a chess opening. Short use can replace long use of expensive target toxic drugs. Because it works, treatment allows a neoadjuvant like next definitive step. Treatment can be changed before it fails. The net effect is a serial cumulative reduction in tumor size and a much-improved chance of high value response allowing ideal surgery.


Lab tests and a database of comparators identify the best empirical drug partners for the specific tumor and individual testing can further refine the choice

(New criteria allow conventional best drugs to be rejected or used in lower dosage). Now even inactive drugs, some which failed in disease specific trials, can become best drugs for the disease. MZB methods have done this in ten plus applications disease and stage specific applications. These new regimens heretofore untested in the specific cancer applications, have produced seeming "best" results.


The laboratory designed drug combinations overcome drug resistance. They allow each drug to have multiple potentiators. Failed drugs can work a second and third time and even produce complete remissions CRs! Overall these core based treatments double survival and triple response. In some ways this methodology takes many drugs the patient has or would normally fail and makes them effective approved drugs work second and third time because they bare ideally partnered, This effectively doubles the drugs available for each patient.


At the same time they are safer and less costly regimens. Safety expands eligibility. Patients now told they can't be treated can be safely treated.


The recommendation strategies above derived from this MZB derived work are "all" firsts. The novel dosage and partner drugs give the drugs a second chance, even drugs found to be inactive in the lab and to have already failed the patient. Table X lists some of those drugs whose efficacy was subsequently supported by independent findings. Many other MZB discovered regimens have not been independently tested in spite of their clinical successes in our practice. MZB Interest focuses on drugs that would fail or new undervalued without these interventions, biologics with superior safety profiles and drugs which were once best in class but have been dropped when hey should have been integrated.


That MZB could identify so many new drug strategies with no false positives in this short time is unique and speaks to the powerful potential of the methodology.

Click here to learn more about how you can
donate to the MZB Center for Cancer Research

Our Process